JP2016539149A - アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン - Google Patents

アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン Download PDF

Info

Publication number
JP2016539149A
JP2016539149A JP2016536539A JP2016536539A JP2016539149A JP 2016539149 A JP2016539149 A JP 2016539149A JP 2016536539 A JP2016536539 A JP 2016536539A JP 2016536539 A JP2016536539 A JP 2016536539A JP 2016539149 A JP2016539149 A JP 2016539149A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
day
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016536539A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539149A5 (cg-RX-API-DMAC10.html
Inventor
トマソ，エマニュエル ディ
トマソ，エマニュエル ディ
ベルマ，マリー−キャロリン
マサケシ，クリスティアン
フリッシュ，クリスティーン
レーヌ シュネル，クリスティアン
レーヌ シュネル，クリスティアン
タボラス，ランジャナ
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2016539149(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2016539149A publication Critical patent/JP2016539149A/ja
Publication of JP2016539149A5 publication Critical patent/JP2016539149A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016536539A 2013-12-06 2014-12-03 アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン Pending JP2016539149A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306679.5 2013-12-06
EP13306679 2013-12-06
PCT/IB2014/066558 WO2015083101A1 (en) 2013-12-06 2014-12-03 Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

Publications (2)

Publication Number Publication Date
JP2016539149A true JP2016539149A (ja) 2016-12-15
JP2016539149A5 JP2016539149A5 (cg-RX-API-DMAC10.html) 2017-12-28

Family

ID=49876516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536539A Pending JP2016539149A (ja) 2013-12-06 2014-12-03 アルファ−アイソフォーム選択的ホスファチジルイノシトール３−キナーゼ阻害剤の投薬レジメン

Country Status (22)

Country Link
US (4) US20170000778A1 (cg-RX-API-DMAC10.html)
EP (2) EP3076969B1 (cg-RX-API-DMAC10.html)
JP (1) JP2016539149A (cg-RX-API-DMAC10.html)
KR (1) KR20160095035A (cg-RX-API-DMAC10.html)
CN (1) CN105979947A (cg-RX-API-DMAC10.html)
AU (2) AU2014358773A1 (cg-RX-API-DMAC10.html)
BR (1) BR112016011811A2 (cg-RX-API-DMAC10.html)
CA (1) CA2930359C (cg-RX-API-DMAC10.html)
CL (1) CL2016001361A1 (cg-RX-API-DMAC10.html)
DK (1) DK3076969T3 (cg-RX-API-DMAC10.html)
ES (1) ES2899167T3 (cg-RX-API-DMAC10.html)
HU (1) HUE057092T2 (cg-RX-API-DMAC10.html)
IL (1) IL245709B (cg-RX-API-DMAC10.html)
MX (1) MX378409B (cg-RX-API-DMAC10.html)
PH (1) PH12016501026A1 (cg-RX-API-DMAC10.html)
PL (1) PL3076969T3 (cg-RX-API-DMAC10.html)
PT (1) PT3076969T (cg-RX-API-DMAC10.html)
RU (1) RU2680246C1 (cg-RX-API-DMAC10.html)
SI (1) SI3076969T1 (cg-RX-API-DMAC10.html)
TN (1) TN2016000179A1 (cg-RX-API-DMAC10.html)
TW (1) TWI666019B (cg-RX-API-DMAC10.html)
WO (1) WO2015083101A1 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533775A (ja) * 2020-07-10 2023-08-04 キュービーディー（キューエス－アイピー）リミテッド 遮断方法

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472289A (zh) * 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502080A (ja) * 2008-09-10 2012-01-26 ノバルティス アーゲー 有機化合物
WO2013083695A1 (en) * 2011-12-06 2013-06-13 Apeiron Biologics Ag Compositions for preventing or treating adverse reactions of egfr inhibition
JP2013542228A (ja) * 2010-11-08 2013-11-21 ノバルティス アーゲー Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
WO2013173283A1 (en) * 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
WO1988007045A1 (fr) 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
EP0383919A4 (en) 1988-02-04 1992-08-05 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0540185A1 (en) 1991-10-10 1993-05-05 Schering Corporation 4'-(N-substituted-N-oxide)staurosporine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
AU3064992A (en) 1991-11-08 1993-06-07 University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
DE69331228T4 (de) 1992-09-21 2002-09-05 Kyowa Hakko Kogyo Co., Ltd. Heilmittel für thrombozytopenia
KR100335584B1 (ko) 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
DK0708772T3 (da) 1993-07-15 2000-09-18 Minnesota Mining & Mfg Imidazo[4,5,-c]pyridin-4-aminer
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
EP1449529B1 (en) 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
ATE446955T1 (de) 1995-03-30 2009-11-15 Pfizer Prod Inc Chinazolinone derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
DE69635966T2 (de) 1995-12-08 2006-11-30 Janssen Pharmaceutica N.V. (Imidazol-5-yl)Methyl-2-Chinolinonderivate als Farnesyl Protein transferase Inhibitoren
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
CN1189562C (zh) 1996-08-02 2005-02-16 吉倪塞思技术公司 针对核糖核苷酸还原酶r1和r2组分的抗肿瘤反义序列
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
KR100743287B1 (ko) 1998-05-29 2007-07-26 수젠, 인크. 피롤기로 치환된 2-인돌리논 단백질 인산화 효소 억제제
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
AR024464A1 (es) 1999-06-25 2002-10-02 Genentech Inc Anticuerpos anti-erbb2 humanizados.
AU6014900A (en) 1999-07-13 2001-01-30 Kyowa Hakko Kogyo Co. Ltd. Staurosporin derivatives
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
EP1246617B1 (en) 1999-12-06 2006-09-13 Rhode Island Hospital Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
EP1274718B1 (en) 2000-04-12 2006-10-18 Genaera Corporation A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
CA2413134C (en) 2000-06-30 2010-05-11 Glaxo Group Limited Quinazoline ditosylate salt compounds
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
EP1404689A1 (en) 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
MXPA04009541A (es) 2002-03-29 2005-01-25 Chiron Corp Benzazoles sustituidos y uso de los mismos como inhibidores de cinasa raf.
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
CA2511646A1 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
JP2014517049A (ja) * 2011-06-21 2014-07-17 ノバルティス アーゲー （ｓ）−ピロリジン−１，２−ジカルボン酸２−アミド１−（｛４−メチル−５−［２−（２，２，２−トリフルオロ−１，１−ジメチル−エチル）−ピリジン−４−イル］−チアゾール−２−イル｝−アミドの多形

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502080A (ja) * 2008-09-10 2012-01-26 ノバルティス アーゲー 有機化合物
JP2013542228A (ja) * 2010-11-08 2013-11-21 ノバルティス アーゲー Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
WO2013083695A1 (en) * 2011-12-06 2013-06-13 Apeiron Biologics Ag Compositions for preventing or treating adverse reactions of egfr inhibition
WO2013173283A1 (en) * 2012-05-16 2013-11-21 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GONZALEZ-ANGULO A M: "SAFETY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF THE [ALPHA]-SPECIFIC PI3K 以下備考", 2013 ASCO ANNUAL MEETING, ABSTRACT NUMBER 2531, 2013/5, JPN5016012066, 31 May 2013 (2013-05-31), ISSN: 0004005302 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023533775A (ja) * 2020-07-10 2023-08-04 キュービーディー（キューエス－アイピー）リミテッド 遮断方法

Also Published As

Publication number Publication date
TWI666019B (zh) 2019-07-21
CL2016001361A1 (es) 2017-02-10
CA2930359A1 (en) 2015-06-11
MX2016007376A (es) 2017-05-11
AU2014358773A1 (en) 2016-06-02
MX378409B (es) 2025-03-10
PT3076969T (pt) 2021-11-23
IL245709B (en) 2021-03-25
HUE057092T2 (hu) 2022-04-28
TN2016000179A1 (en) 2017-10-06
AU2017245292B2 (en) 2018-09-27
DK3076969T3 (da) 2021-11-22
EP4000619A1 (en) 2022-05-25
US20200069670A1 (en) 2020-03-05
EP3076969B1 (en) 2021-09-01
KR20160095035A (ko) 2016-08-10
HK1223549A1 (zh) 2017-08-04
RU2680246C1 (ru) 2019-02-19
TW201609096A (zh) 2016-03-16
BR112016011811A2 (pt) 2017-08-08
CN105979947A (zh) 2016-09-28
WO2015083101A1 (en) 2015-06-11
US20210196696A1 (en) 2021-07-01
SI3076969T1 (sl) 2021-12-31
PH12016501026A1 (en) 2016-07-04
US20180078540A1 (en) 2018-03-22
AU2017245292A1 (en) 2017-11-02
US20170000778A1 (en) 2017-01-05
IL245709A0 (en) 2016-07-31
PL3076969T3 (pl) 2022-01-17
US10434092B2 (en) 2019-10-08
EP3076969A1 (en) 2016-10-12
CA2930359C (en) 2022-03-01
ES2899167T3 (es) 2022-03-10

Similar Documents

Publication Publication Date Title
JP6058009B2 (ja) Ｐｉ３ｋ−およびｍｅｋ−阻害剤の相乗的な組合せ
KR102064626B1 (ko) Tor 키나제 억제자 복합 치료법을 사용한 비소세포 폐암의 치료 방법
EP2885003B1 (en) Combination of pi3k inhibitor and c-met inhibitor
KR20180019230A (ko) 나노입자 조성물에 대한 바이오마커
KR20160007502A (ko) 디하이드로피라지노-피라진을 사용한 암의 치료
JP2016522247A (ja) 組合せ医薬
US20210196696A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
KR20230107606A (ko) 저등급 신경교종 치료를 위한 raf 억제제
WO2018060833A1 (en) Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
KR20180073674A (ko) 포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
HK1223549B (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190402